RESUMEN
PURPOSE: The study aimed to discern the intent to treat with the therapeutic agents prescribed first or second line in the following eye conditions: neovascular age-related macular Degeneration (nAMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and myopic maculopathy with choroidal neovascularization (MMNV). The study also aimed to distinguish the ophthalmologists' intended treatment for their patients from those that they would prescribe for themselves if they were affected by the above macular conditions. METHODS: The study utilized an online survey of 243 French ophthalmologists practicing medical retina, with males accounting for 54.3% of the participants. Data was obtained using a questionnaire that focused on the ophthalmologists' experience with various agents as well as their first and second line choices for nAMD, DME, RVO, and MMNV. RESULTS: The vast majority of French ophthalmologists (99%) had experience with the most widely used anti-vascular endothelial growth factors (anti-VEGFs); ranibizumab, bevacizumab, and aflibercept. Fewer than 8% reported experience with anti-VEGF drug reservoirs, biosimilars, or faricimab. The study findings also showed ranibizumab and aflibercept as the commonly prescribed first line choices for the above-mentioned ocular conditions. For the second line choice, the study showed that aflibercept and dexamethasone intravitreal implants were the most common across the four retinal conditions studied. The only difference in intent to treat for "patients" versus "yourself" was for biosimilars (0% to 0.8%, P=0.001). CONCLUSION: The findings regarding the first and second line choices for the mentioned ocular disorders were found to agree with the findings of published literature currently used in practice, with a tendency to prefer ranibizumab as first line therapy for neovascular disorders and aflibercept as first line therapy for macular edema. In addition, there were no differences between choices for first and second line therapy for patients vs. ophthalmologists.
Asunto(s)
Oftalmólogos , Pautas de la Práctica en Medicina , Enfermedades de la Retina , Humanos , Masculino , Oftalmólogos/estadística & datos numéricos , Enfermedades de la Retina/tratamiento farmacológico , Enfermedades de la Retina/epidemiología , Enfermedades de la Retina/terapia , Femenino , Pautas de la Práctica en Medicina/estadística & datos numéricos , Pautas de la Práctica en Medicina/normas , Francia/epidemiología , Persona de Mediana Edad , Encuestas y Cuestionarios , Inhibidores de la Angiogénesis/administración & dosificación , Adulto , Oftalmología/estadística & datos numéricos , Oftalmología/normas , Oclusión de la Vena Retiniana/tratamiento farmacológico , Oclusión de la Vena Retiniana/complicaciones , Oclusión de la Vena Retiniana/epidemiologíaRESUMEN
PURPOSE: To evaluate the association between age-related macular degeneration (AMD) and periodontal disease, two frequent conditions in the elderly, with some risk factors in common. METHODS: Single center, pilot, case-control study performed in a center specialized in the diagnosis and management of AMD. Periodontal status was evaluated in 43 AMD patients and 19 controls. Fundus examination and a complete periodontal examination were performed in all subjects. RESULTS: AMD patients have a greater percentage of 3-4mm clinical attachment loss compared to controls (47% vs. 38%, [P=0.039]). However, no significant difference was found between the groups with regard to the prevalence of severe periodontitis. CONCLUSIONS: These results suggest an association between AMD and attachment loss characteristic of periodontal disease and support the need for larger prospective studies to elucidate the relationships between these 2 highly prevalent and potentially severe diseases.
Asunto(s)
Degeneración Macular , Enfermedades Periodontales , Anciano , Estudios de Casos y Controles , Humanos , Degeneración Macular/complicaciones , Degeneración Macular/diagnóstico , Degeneración Macular/epidemiología , Enfermedades Periodontales/complicaciones , Enfermedades Periodontales/diagnóstico , Enfermedades Periodontales/epidemiología , Estudios Prospectivos , Factores de RiesgoAsunto(s)
Testimonio de Experto , Inyecciones Intravítreas/normas , Pautas de la Práctica en Medicina/normas , Anestésicos Locales/administración & dosificación , Lista de Verificación/normas , Francia , Hospitales/normas , Humanos , Higiene/normas , Inyecciones Intravítreas/métodos , Inyecciones Intravítreas/tendencias , Monitoreo Fisiológico/métodos , Monitoreo Fisiológico/normas , Oftalmología/organización & administración , Oftalmología/normas , Pautas de la Práctica en Medicina/organización & administración , Pautas de la Práctica en Medicina/tendencias , Administración de la Seguridad/organización & administración , Administración de la Seguridad/normas , Sociedades Médicas/organización & administración , Sociedades Médicas/normasAsunto(s)
Anemia Hemolítica Autoinmune/etiología , Fibrina/análisis , Fóvea Central/patología , Síndromes Mielodisplásicos/complicaciones , Escotoma/etiología , Anciano , Anemia Hemolítica Autoinmune/terapia , Terapia Combinada , Femenino , Angiografía con Fluoresceína , Fóvea Central/química , Humanos , Imagen Multimodal , Imagen Óptica , Neumonía por Pneumocystis/complicaciones , Neumonía Asociada al Ventilador/complicaciones , Hemorragia Retiniana/diagnóstico por imagen , Hemorragia Retiniana/etiología , Escotoma/diagnóstico por imagen , Tomografía de Coherencia ÓpticaAsunto(s)
Angiografía/métodos , Embolia por Colesterol/diagnóstico por imagen , Oclusión de la Arteria Retiniana/diagnóstico por imagen , Tomografía de Coherencia Óptica , Anciano , Embolia por Colesterol/complicaciones , Femenino , Humanos , Arteria Retiniana/diagnóstico por imagen , Oclusión de la Arteria Retiniana/complicacionesRESUMEN
PURPOSE: To update the recommendations of the France Macula Federation for the diagnosis of wet age-related macular degeneration (AMD). METHODS: Analysis of literature and expert opinion. RESULTS: The FMF recommends diagnosing wet AMD by combining the results of fundus examination (or color or monochromatic fundus photographs), optical coherence tomography (OCT) showing exudative signs, and morphological visualization of the neovascular membrane, which may be obtained non-invasively (OCT-angiography) or invasively (fluorescein and/or indocyanine green angiography). Under optimal conditions in which all these tools are available, the FMF recommends using non-invasive methods as first-line tools and resorting to dye angiography if diagnostic doubt remains. CONCLUSION: As observed in other fields of medical imaging, non-invasive methods are preferred to invasive methods for the diagnosis of wet AMD, while the latter are reserved for more difficult cases.
Asunto(s)
Técnicas de Diagnóstico Oftalmológico/normas , Degeneración Macular Húmeda/diagnóstico , Testimonio de Experto , Angiografía con Fluoresceína/métodos , Angiografía con Fluoresceína/normas , Francia , Humanos , Mácula Lútea/diagnóstico por imagen , Mácula Lútea/patología , Oftalmología/organización & administración , Oftalmología/normas , Sociedades Médicas/normas , Tomografía de Coherencia Óptica/métodos , Tomografía de Coherencia Óptica/normasRESUMEN
PURPOSE: To update the recommendations of the France Macula Federation for treatment of wet age-related macular degeneration (AMD). METHODS: Analysis of literature and expert opinion. RESULTS: The FFM recommends initiating anti-VEGF therapy as soon as possible after diagnosis of exudative AMD. There has been no major change in the last several years concerning the procedure of intravitreal injection itself. However, the litigious points are discussed: simultaneous bilateral injection; antibiotic therapy; medico-legal aspects. All anti-VEGF strategies possess advantages and limitations. The strategy should be left to the ophthalmologists' preference. However, the chosen strategy should be explained to patients and strictly followed. CONCLUSION: The treatment of wet-AMD is more precisely codified than before. However, various strategies still coexist.
Asunto(s)
Degeneración Macular Húmeda/terapia , Inhibidores de la Angiogénesis/administración & dosificación , Antibacterianos/administración & dosificación , Bevacizumab/administración & dosificación , Testimonio de Experto , Francia , Humanos , Inyecciones Intravítreas , Mácula Lútea/patología , Oftalmología/organización & administración , Oftalmología/normas , Ranibizumab/administración & dosificación , Sociedades Médicas/organización & administración , Sociedades Médicas/normas , Degeneración Macular Húmeda/patologíaRESUMEN
Wet macular degeneration remains a major cause of visual impairment in people over 55years. Through a group of experts belonging to the Federation France Macula, we review the treatment of wet AMD and provide recommendation with a 3 phases protocol called IOI.
Asunto(s)
Monitoreo Fisiológico/métodos , Guías de Práctica Clínica como Asunto , Medicina de Precisión/métodos , Degeneración Macular Húmeda/terapia , Anciano , Anciano de 80 o más Años , Francia , Humanos , Inyecciones Intravítreas , Persona de Mediana Edad , Monitoreo Fisiológico/normas , Pautas de la Práctica en Medicina/normas , Medicina de Precisión/normasRESUMEN
INTRODUCTION: Pseudoxanthoma elasticum (PXE), a rare hereditary connective tissue disorder, may be complicated by angioid streaks (AS) and choroidal neovascularization (CNV), which may lead to irreversible loss of visual acuity (VA). Here we describe the safety and efficacy of ranibizumab in patients with CNV secondary to PXE. METHODS: A multicenter (n=23), observational study of a retrospective/prospective cohort, performed under real world conditions in France in all patients with CNV secondary to PXE who received at least one ranibizumab injection as of October 2011. The study objectives were to describe the mean annual number and reason for ranibizumab injections since initiation, evolution of best-corrected visual acuity (BCVA by Early Treatment Diabetic Retinopathy Study [ETDRS] letters), and safety. RESULTS: Patients (n=72; 98 eyes) had a mean age of 59.6±8.3years and consisted of 54.2% men. The criterion for retreatment was based mainly on loss of VA, progression of CNV and angiographic leakage. CNV was primarily subfoveal or juxtafoveal (73.4%), and the initial mean VA was 64.6 ETDRS letters. On average, visual acuity of all eyes analyzed was relatively stable during the 2-year follow-up (62.3 letters vs 64.6 letters at the first injection), and 88.6% of eyes maintained VA between -15 and +15 letters or gained over 15 letters. No deaths or new intolerances were described. CONCLUSIONS: These results showed that ranibizumab was able to maintain stable VA in clinical practice for at least 2years in patients with CNV secondary to PXE, and to significantly reduce the frequency of neovascularization relapses, with a limited number of injections. The treatment was well tolerated by the patients.
Asunto(s)
Neovascularización Coroidal/tratamiento farmacológico , Seudoxantoma Elástico/tratamiento farmacológico , Ranibizumab/uso terapéutico , Adulto , Anciano , Anciano de 80 o más Años , Neovascularización Coroidal/etiología , Estudios de Cohortes , Femenino , Estudios de Seguimiento , Francia , Humanos , Masculino , Persona de Mediana Edad , Seudoxantoma Elástico/complicaciones , Ranibizumab/efectos adversos , Resultado del TratamientoRESUMEN
BACKGROUND AND OBJECTIVES: High myopia (HM), which affects 0.9 to 3.1% of the population, is a major cause of vision loss. The purpose of this investigation was to study and evaluate the impact of their high myopia on the daily lives of patients and to better understand their expectations in order to better meet their needs. MATERIALS AND METHODS: The survey was conducted between February 19 and March 21, 2014. To be eligible, patients had to have myopia of at least -8 diopters and be over 40 years of age, with or without myopic complications. Patients' degree of myopia was defined as the optical prescription of their worse eye. The 123 patients included were interviewed by phone using a questionnaire developed and validated by a scientific committee composed of experts and members of the patients' Association against myopic maculopathy (AMAM). The phone interview, semi-structured, lasted 20 minutes. RESULTS: On average, myopia was -11.7 diopters. Women accounted for 71% of the population, 89% of patients were under 65 years and were mostly professionals (65%). Over half of the subjects reported myopic complications; 5% of patients had choroidal neovascularization (CNV). Only 29% had been informed of the risk of CNV or maculopathy. HM was a handicap in sports for 64% of patients, in leisure activities for 51%, and in professional activities for more than a quarter (28%). Only 56% of HM patients reported living perfectly well with their condition. CONCLUSIONS: This survey is the first study on the daily life of people with HM aiming to analyze their social and emotional environment. It shows that HM has a profound impact on the daily lives of patients and may affect social life and professional activity. Most myopic patients possess incomplete or unclear information about the nature and risk of myopic complications. They expressed the desire to be better informed about their condition earlier, before the onset of complications.
Asunto(s)
Actitud Frente a la Salud , Miopía/psicología , Actividades Cotidianas , Adulto , Anciano , Neovascularización Coroidal/psicología , Comorbilidad , Cultura , Emociones , Femenino , Necesidades y Demandas de Servicios de Salud , Encuestas Epidemiológicas , Humanos , Masculino , Persona de Mediana Edad , Miopía/complicaciones , Ocupaciones , Educación del Paciente como Asunto , Calidad de Vida , Riesgo , Medio SocialRESUMEN
INTRODUCTION: Two or three systematic intravitreal injections (IVT) may be prescribed in a PRN approach to treat an exudative recurrence of neovascular age-related macular degeneration (AMD), according to the phenotype. Optical coherence tomography (OCT) may be performed immediately before the 2nd or the 3rd scheduled IVT, making it possible to cancel the procedure in the absence of exudation. The aim of the study was to evaluate the usefulness of this OCT examination and to assess the percentage of IVT cancelled, in order to evaluate a potential medico-economic benefit. METHODS: Monocentric retrospective study, in which were included 292 consecutive eyes with exudative recurrence of AMD, for which 2 or 3 IVT were scheduled between January 1st and April 30th, 2014. All patients received a first systematic IVT in the seven days following the diagnosis. Then, on the days of the 2nd and 3rd scheduled IVT, each patient had a visual acuity measurement and a Spectral domain-OCT (Spectralis, HRA Heidelberg Engineering). This measurement allowed for the IVT to be either performed as scheduled or cancelled. Both ranibizumab and aflibercept were used. A Chi(2) test was used to compare the qualitative variables and an adjusted Wilcoxon test for the quantitative values. RESULTS: Two hundred and ninety-two consecutive eyes were included; 172 in the "2 scheduled IVT" group (group A) and 120 in the "3 scheduled IVT" group (group B). At the first follow-up, 37.6% of scheduled IVT were cancelled after the OCT (44.1% in group A and 28.3% in group B). At the second follow-up, 33.3% of IVT were cancelled in group B. Overall, 150/412 (36.4%) IVT were avoided in this series. Presence of serous retinal detachment, retinal edema and increased central macular thickness were statistically correlated with confirmation of the scheduled IVT at the two follow-ups (P<0.001, P<0.001 and P=0.002, respectively). A savings of 429.80 per patient was calculated during this short period of follow-up. CONCLUSION: An average non-injection rate of 36.4% of scheduled IVT was found in this protocol of management of recurrences with OCT performed the day of IVT. This protocol allowed to avoid unnecessary IVT one-third of the time and appeared highly cost-effective.
Asunto(s)
Inhibidores de la Angiogénesis/uso terapéutico , Ranibizumab/uso terapéutico , Receptores de Factores de Crecimiento Endotelial Vascular/uso terapéutico , Proteínas Recombinantes de Fusión/uso terapéutico , Tomografía de Coherencia Óptica/métodos , Procedimientos Innecesarios , Degeneración Macular Húmeda/patología , Anciano , Anciano de 80 o más Años , Inhibidores de la Angiogénesis/administración & dosificación , Inhibidores de la Angiogénesis/economía , Ahorro de Costo , Análisis Costo-Beneficio , Manejo de la Enfermedad , Exudados y Transudados , Femenino , Humanos , Inyecciones Intravítreas , Masculino , Persona de Mediana Edad , Papiledema/diagnóstico , Papiledema/etiología , Ranibizumab/administración & dosificación , Ranibizumab/economía , Receptores de Factores de Crecimiento Endotelial Vascular/administración & dosificación , Receptores de Factores de Crecimiento Endotelial Vascular/economía , Proteínas Recombinantes de Fusión/administración & dosificación , Proteínas Recombinantes de Fusión/economía , Recurrencia , Desprendimiento de Retina/diagnóstico , Desprendimiento de Retina/etiología , Estudios Retrospectivos , Tomografía de Coherencia Óptica/economía , Procedimientos Innecesarios/economía , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Agudeza Visual , Degeneración Macular Húmeda/complicaciones , Degeneración Macular Húmeda/tratamiento farmacológico , Degeneración Macular Húmeda/economíaRESUMEN
BACKGROUND: Optical coherence tomography has significantly changed the approach to vitreomacular diseases, including macular holes (MH). OCT provides information on differential diagnoses (lamellar hole, pseudo-hole), the MH size, the status of the vitreous, and the status of the various retinal layers. The evolution of diagnostic tools and treatment justifies the need for an update of the current classification of vitreomacular diseases. METHOD: A group of retina specialists met several times to discuss the international classification, recently published by The International Vitreomacular Traction Study Group, focusing on vitreomacular adhesion (VMA), vitreomacular traction (VMT) and MH. It was compared to the classification currently used in France, based on the ophthalmoscopic system of Gass, then further delineated by Gaudric's OCT studies, in order to suggest a French adaptation to the international classification. RESULTS: An adapted classification for clinical use in France and in connection with the international classification is proposed. VMA are classified as an "associated" or "isolated" VMA respectively with or without macular disease. MH are distinguished as "primary" or "secondary" MH depending on whether the etiology is known or not, and classified as "small", "medium" and "large" depending on the size of the hole, and according to the presence or absence of VMT. Finally, VMT are described according to presence or absence of an epimacular membrane and according to the width of the adhesion.
Asunto(s)
Oftalmopatías/clasificación , Perforaciones de la Retina/clasificación , Cuerpo Vítreo , Humanos , Tomografía de Coherencia ÓpticaRESUMEN
Age related macular degeneration (AMD) is a pathological aging of the macula, brought about by the interaction of genetic and environmental factors. It induces geographic atrophy of the retina and/or choroidal neovascularization. In the latter, abnormal vessels develop from the choriocapillaris, with the involvement of VEGF (vascular endothelial growth factor). The VEGF family includes several factors, including VEGF-A, B, C, D, F and PlGF (placental growth factor). Their biological properties and their affinities to the VEGFR1, VEGFR2 and VEGFR3 receptors found on endothelial cells differ. Exudative AMD involves mainly VEGF-A and VEGF-R2. Anti-VEGF agents used in ophthalmology (ranibizumab, bevacizumab and aflibercept) are designed to primarily target this pathway. In vitro, all have sufficient affinity to their ligands. Their therapeutic efficacy must therefore be judged based on clinical criteria. In clinical practice, the minimum number of injections required for a satisfactory result appears to be comparable with all the three. The few available studies on therapeutic substitutions of anti-VEGF compounds suggest that some patients may benefit from substituting the anti-VEGF in cases of an unsatisfactory response to an initial molecule. Although local side effects, including increased risk of geographic atrophy, and systemic effects, including vascular accidents, have been suggested, these risks remain low, specially compared to the benefits of the treatment. Differences in safety between anti-VEGF are theoretically possible but unproven.
Asunto(s)
Inhibidores de la Angiogénesis/uso terapéutico , Degeneración Macular/tratamiento farmacológico , Receptores de Factores de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Envejecimiento/fisiología , Anticuerpos Monoclonales Humanizados/uso terapéutico , Bevacizumab , Neovascularización Coroidal/tratamiento farmacológico , Tolerancia a Medicamentos , Humanos , Degeneración Macular/fisiopatología , Ensayos Clínicos Controlados Aleatorios como Asunto , Ranibizumab , Receptores de Factores de Crecimiento Endotelial Vascular/uso terapéutico , Proteínas Recombinantes de Fusión/uso terapéutico , Retina/fisiología , Factores de RiesgoRESUMEN
Myopic choroidal neovascularization is a frequent cause of visual acuity loss that can affect young individuals. Through a group of experts belonging to the Fédération France Macula, we review the treatment of myopic choroidal neovascularization and provide recommendations related to the treatment of this complication.
Asunto(s)
Neovascularización Coroidal/terapia , Neovascularización Coroidal/etiología , Árboles de Decisión , Humanos , Miopía/complicaciones , Fototerapia , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidoresAsunto(s)
Inhibidores de la Angiogénesis/uso terapéutico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Factor A de Crecimiento Endotelial Vascular/antagonistas & inhibidores , Inhibidores de la Angiogénesis/administración & dosificación , Anticuerpos Monoclonales Humanizados/administración & dosificación , Retinopatía Diabética/diagnóstico , Retinopatía Diabética/tratamiento farmacológico , Reposicionamiento de Medicamentos , Humanos , Inyecciones Intravítreas , Degeneración Macular/diagnóstico , Degeneración Macular/tratamiento farmacológico , Edema Macular/diagnóstico , Edema Macular/tratamiento farmacológico , Pronóstico , Ranibizumab , Resultado del TratamientoAsunto(s)
Anticuerpos Monoclonales Humanizados/uso terapéutico , Degeneración Macular/tratamiento farmacológico , Inhibidores de la Angiogénesis/efectos adversos , Inhibidores de la Angiogénesis/uso terapéutico , Anticuerpos Monoclonales Humanizados/efectos adversos , Bevacizumab , Ensayos Clínicos como Asunto , Humanos , Degeneración Macular/epidemiología , Degeneración Macular/fisiopatología , Ranibizumab , Resultado del Tratamiento , Estados Unidos , Enfermedades Vasculares/inducido químicamente , Enfermedades Vasculares/epidemiología , Agudeza Visual/efectos de los fármacosRESUMEN
A full interpretation of indocyanine green angiography images involves not only optical issues but also pharmacokinetic and biochemical aspects. These issues may involve biochemical changes in the fluorescence yield and the affinity of the molecule for lipoproteins and phospholipids. For age related macular degeneration (AMD), the advent of photodynamic therapy and especially anti-VEGF drugs has increased the use of OCT in assessing treatment response and guiding retreatment. The ease and advantages of OCT have become increasingly associated with a decreasing interest in ICG angiography, which is becoming less well suited for the current management of AMD. An aging population, the efficacy of anti-VEGF drugs and the relative rarity of polypoidal choroidal vasculopathy (PCV) in Europe are factors contributing to our proportional increase in AMD patients. However, aside from AMD, the indications for ICG angiography remain little changed over the last decade: it remains important in diagnosing PCV and choroidal hemangiomas, since their prognosis and treatment are specific. Similarly, for certain inflammatory conditions such as Multiple Evanescent White Dot Syndrome (MEWDS) or Birdshot chorioretinitis, the value of ICG angiography remains significant. In addition, for the treatment of chronic Central Serous Chorioretinopathy, ICG angiography helps to find sites of leakage which otherwise might have been missed. The ICG angiographic appearance in this setting may also have prognostic value. Although the indications for ICG angiography are currently decreasing for AMD, these other conditions represent a large enough number of patients to justify the continued use of this original test, which remains complementary to other chorioretinal imaging techniques.